A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Abb Vie Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 45,692 shares of ABBV stock, worth $8.22 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
45,692
Previous 46,082 0.85%
Holding current value
$8.22 Million
Previous $7.9 Million 14.17%
% of portfolio
0.1%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $63,897 - $77,738
-390 Reduced 0.85%
45,692 $9.02 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $2.4 Million - $2.8 Million
-15,501 Reduced 25.17%
46,082 $7.9 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $2.74 Million - $3.13 Million
17,166 Added 38.65%
61,583 $11.2 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $4.01 Million - $4.52 Million
-29,168 Reduced 39.64%
44,417 $6.88 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $2.51 Million - $2.91 Million
18,800 Added 34.32%
73,585 $11 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $3.78 Million - $4.7 Million
28,499 Added 108.42%
54,785 $7.38 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $825,144 - $950,277
-5,706 Reduced 17.84%
26,286 $4.19 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $3.03 Million - $3.64 Million
-21,934 Reduced 40.67%
31,992 $5.17 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $226,546 - $259,833
1,688 Added 3.23%
53,926 $7.24 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $634,152 - $806,215
4,608 Added 9.67%
52,238 $8 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $1.18 Million - $1.47 Million
-8,962 Reduced 15.84%
47,630 $7.72 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $5.23 Million - $6.62 Million
-48,702 Reduced 46.25%
56,592 $7.66 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $5.06 Million - $5.75 Million
47,567 Added 82.4%
105,294 $11.4 Million
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $1.07 Million - $1.19 Million
-10,187 Reduced 15.0%
57,727 $6.5 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $819,013 - $901,635
8,006 Added 13.36%
67,914 $7.35 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $2.03 Million - $2.74 Million
25,174 Added 72.48%
59,908 $6.42 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $14.2 Million - $16.6 Million
-164,931 Reduced 82.6%
34,734 $3.04 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $4.95 Million - $6.62 Million
67,425 Added 50.99%
199,665 $19.6 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $3.44 Million - $5.22 Million
-53,384 Reduced 28.76%
132,240 $10.1 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $2.32 Million - $2.9 Million
-32,101 Reduced 14.74%
185,624 $16.4 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $12 Million - $14.4 Million
-190,784 Reduced 46.7%
217,725 $16.5 Million
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $2.76 Million - $3.53 Million
42,056 Added 11.48%
408,509 $29.7 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $4.87 Million - $5.74 Million
63,196 Added 20.84%
366,453 $29.5 Million
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $1.79 Million - $2.21 Million
-22,979 Reduced 7.04%
303,257 $28 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $5.65 Million - $6.28 Million
-63,563 Reduced 16.31%
326,236 $30.9 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $4.94 Million - $5.84 Million
-55,015 Reduced 12.37%
389,799 $36.1 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $18.9 Million - $25.3 Million
205,570 Added 85.92%
444,814 $42.1 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $14.3 Million - $15.7 Million
-159,593 Reduced 40.01%
239,244 $23.1 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $27.9 Million - $35.6 Million
398,837
398,837 $35.4 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.